Literature DB >> 7413020

Stimulation of in vitro prolactin release by vasoactive intestinal peptide.

A Enjalbert, S Arancibia, M Ruberg, M Priam, M T Bluet-Pajot, W H Rotsztejn, C Kordon.   

Abstract

VIP stimulated prolactin secretion from incubated rat hemipituitaries. Under the same conditions, the secretion of GH, LH, FSH was not affected. The stimulation of prolactin was dose-dependent, with an apparent affinity of VIP of 10.9 +/- 3.1 nM and a maximal stimulation of 57.7 +/- 4.2%. Secretin, a structurally related peptide, was also active at higher concentrations whereas another partial analogue, glucagon, was ineffective. The effect of VIP was not blocked by alpha-flupentixol, a potent dopaminergic antagonist, at concentrations which antagonized the dopamine inhibition of prolactin secretion. Stimulation by VIP and TRH was additive. Neither Met-enkephalin nor naloxone interfered with the response to VIP. It thus seems that specific VIP receptors are present on pituitary prolactin cells. VIP, present in the mediobasal hypothalamus and detected in the hypothalamo-hypophyseal portal blood therefore is a good candidate as a physiological PRF.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7413020     DOI: 10.1159/000123074

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

1.  Vasoactive intestinal peptide (VIP) mediates the effect of estrogens on the dopaminergic tone in the hypothalamic-pituitary axis of ovariectomized (OVX) rats.

Authors:  M Lasaga; A Seilicovich; D Pisera; M C Díaz; M F Befumo; B H Duvilanski
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

2.  Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study.

Authors:  D W Hsu; P N Riskind; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  Immunocytochemistry of four mixed pituitary adenomas and intrasellar gangliocytomas associated with different clinical syndromes: acromegaly, amenorrhea-galactorrhea, Cushing's disease and isolated tumoral syndrome.

Authors:  J Y Li; O Racadot; M Kujas; M Kouadri; F Peillon; J Racadot
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Cis-unsaturated free fatty acids block VIP-mediated GH and PRL secretion by perturbing the cAMP/protein kinase A pathway.

Authors:  F R Pérez; J P Camiña; C Menéndez; A Beiras; X Casabiell; F F Casanueva
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

5.  Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary.

Authors:  P Onali; J P Schwartz; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

6.  Rapid glucocorticoid inhibition of vasoactive intestinal peptide-induced cyclic AMP accumulation and prolactin release in rat pituitary cells in culture.

Authors:  W H Rotsztejn; M Dussaillant; F Nobou; G Rosselin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

Review 7.  The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone.

Authors:  S Nicosia; D Oliva; G Giannattasio; A Spada
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.